Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential

GLP-1 receptor agonists show strong preclinical neuroprotective potential in Alzheimer’s disease through effects on insulin signaling, neuroinflammation, amyloid, tau, and brain metabolism. Human evidence remains mixed, with observational studies suggesting lower dementia risk but randomized trials yet to demonstrate a clinically meaningful disease-modifying benefit.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

The obesity-microbiome story is more complicated than ‘good’ and ‘bad’ bacteria

This review finds that obesity is linked to reciprocal interactions between diet, the gut microbiome, microbial metabolites, and host metabolic pathways that influence appetite, insulin sensitivity, inflammation, and energy balance across the lifespan. It highlights diet as a particularly tractable way to influence this system, while emphasizing that microbiome changes associated with GLP-1 therapies remain difficult to separate from weight loss and that functional multi-omics approaches may help enable more personalized interventions.

3 Sep 2026

Semaglutide extended lifespan in older female mice, but that was not the only finding

Late-life semaglutide treatment slowed age-related physiological decline, attenuated multiple molecular hallmarks of aging, and extended median lifespan from 742 to 834 days in aged female mice. The drug reproduced many effects of calorie restriction while providing additional benefits in exploratory behavior, spatial memory, and glucose control, suggesting that some effects extend beyond reduced calorie intake alone.

3 Sep 2026

Why addiction researchers are paying closer attention to GLP-1 drugs

A Journal of Clinical Investigation Viewpoint highlights growing evidence that GLP-1 receptor agonists, particularly semaglutide, may reduce alcohol consumption and some other substance-related outcomes by acting on brain systems involved in reward, motivation, stress, and emotion. However, the authors caution that efficacy for substance use disorders is not yet firmly established and call for further research into optimal dosing, treatment duration, patient selection, mechanisms, and effects across different addictions.

2 Sep 2026

Semaglutide extends lifespan and slows physiological aging in healthy mice

A National Institutes of Health (NIH)-funded study has shown that the GLP-1 drug semaglutide extended lifespan in older, healthy mice by tempering the detrimental effects of aging.

2 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

31 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

New guidelines simplify heart failure phenotypes into two groups

Reflecting improved understanding and treatment advances, new European Society of Cardiology (ESC) Guidelines on heart failure have been published online today in the European Heart Journal and will be presented at ESC Congress 2026 this afternoon.

28 Aug 2026

GLP-1 drugs may reshape obesity care, but clinicians still have questions

Interviews with 11 healthcare professionals in a UK specialist weight management service found generally positive attitudes toward injectable GLP-1 drugs, alongside limited formal training and uncertainty about how the medications should be integrated with behavioral care. Participants anticipated potential benefits for confidence and weight management but also raised concerns about treatment discontinuation, behavioral engagement, and evolving professional responsibilities.

26 Aug 2026

Semaglutide’s heart benefits may partly involve reduced inflammation

A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.

24 Aug 2026

UC Berkeley researchers find new potential treatment for obesity and diabetes

Over the past five years, medications called GLP-1s have revolutionized the treatment of metabolic disorders like obesity, diabetes and fatty liver diseases.

21 Aug 2026

Semaglutide trial targets people with liver disease, obesity and alcohol addiction

A new study -- co-led by the University of Plymouth, University Hospitals Plymouth NHS Trust, and the NIHR Biomedical Research Centre: Nottingham -- is being launched into a treatment for people impacted by liver disease, obesity and alcohol addiction.

19 Aug 2026

Semaglutide slows blood protein signature linked to future dementia risk

A post hoc analysis of 2,970 older SELECT participants found that semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk. Over 104 weeks, semaglutide produced larger effects on modeled 5-year than 20-year dementia risk, but whether these biomarker changes translate into less cognitive decline or dementia remains unknown.

10 Aug 2026

New review links obesity with accelerated biological aging mechanisms

The global rise in obesity and population aging represents a major public health challenge, with growing evidence suggesting that excess body fat not only increases the risk of chronic disease but may also accelerate the biological aging process.

6 Aug 2026

Ten-million-person study links semaglutide to lower COVID-19 mortality

Researchers analyzing claims from more than 10.1 million commercial insurance and Medicare Advantage enrollees found that semaglutide use was associated with a 49% lower adjusted hazard of COVID-19-related death. The observational findings corroborate earlier SELECT trial results but do not establish causation, making further prospective research essential.

30 Jul 2026

Oral semaglutide reduces heavy drinking in adults with alcohol use disorder

A clinical trial led by researchers at CU Anschutz has found that oral semaglutide, a medication widely used for diabetes and weight loss, reduces heavy drinking in adults with Alcohol Use Disorder (AUD).

29 Jul 2026

Taste preference genes drive overeating and metabolic disease risk

Ever wonder why some people crave sweets while others can take them or leave them? Preliminary findings from a new study suggest that people who carry certain genetic variants associated with a preference for sweet or fatty tastes not only tend to eat more of these foods but also have a higher risk of obesity and type 2 diabetes as a result.

27 Jul 2026

Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits

Newer GLP-1 receptor agonists, including semaglutide and tirzepatide, were associated with fewer alcohol-related ED visits or hospitalizations among adults with alcohol use disorder and type 2 diabetes or obesity.

24 Jul 2026

GLP-1 receptor agonists may increase hair loss risk

Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ today.

22 Jul 2026

Generic semaglutide could improve diabetes treatment affordability in Canada

In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that the anticipated price reductions of up to 70% will dramatically increase both the cost-effectiveness and health system affordability of therapy options for patients with type 2 diabetes and high cardiorenal risk.

22 Jul 2026